Research programme: cancer therapeutics - FORMA/Moffitt Cancer Center

Drug Profile

Research programme: cancer therapeutics - FORMA/Moffitt Cancer Center

Alternative Names: HDAC modulators - FORMA/Moffitt

Latest Information Update: 25 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FORMA Therapeutics; H. Lee Moffitt Cancer Center and Research Institute
  • Class Small molecules
  • Mechanism of Action Histone deacetylase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 23 Sep 2014 FORMA Therapeutics and Moffitt Cancer Center agree to co-develop drugs in USA for Cancer
  • 23 Sep 2014 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top